AI Article Synopsis
- Viral load testing for HIV-1 in low-resource areas faces challenges, despite the availability of antiretroviral therapy (ART).
- This study evaluated the Cavidi version 3.0 assay, which measures plasma reverse transcriptase activity, against standard molecular viral load tests.
- Results showed Cavidi version 3.0 has an overall sensitivity of about 87% for detecting high viral loads (over 1000 copies/ml), and it is more cost-effective and user-friendly than traditional methods while being suitable for monitoring both HIV-1 and HIV-2.
Article Abstract
Viral load testing for human immunodeficiency virus 1 (HIV-1) in resource-poor settings continues to be a challenge. Although antiretroviral therapy (ART) is being made available in developing countries, monitoring of viral load is not being done on a regular basis. The purpose of this study was to assess the utility of Cavidi version 3.0, which measures the plasma reverse transcriptase (RT) activity and compare its performance with molecular HIV viral load assays. In all, 125 HIV-1 and 13 HIV-2 positive samples were analyzed. The overall sensitivity of the assay was 86.8% and 94.1% for viral load >1000 copies/ml measured by Qiagen Artus HIV-1 RG RT PCR and Abbott RealTime HIV-1 PCR assays, respectively. Compared with the routine molecular viral load assays, Cavidi version 3.0 is inexpensive, user-friendly, the expenditure on infrastructure is minimal, and it can be used for monitoring of both HIV types.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/23744235.2015.1122832 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!